New hope for heart inflammation sufferers: drug switch study launches

NCT ID NCT07288216

Recruiting now Disease control Sponsor: Kiniksa Pharmaceuticals International, plc Source: ClinicalTrials.gov ↗

First seen Jan 05, 2026 · Last updated Jun 16, 2026 · Updated 29 times

Summary

This study tests if a new drug called KPL-387 can safely replace standard treatments for people with recurrent pericarditis (repeated heart lining inflammation). About 80 adults whose condition is well-controlled on current therapy will switch to KPL-387 alone. Researchers will track how many stay free of flare-ups over 16 weeks and beyond.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Investigational Site 001
RECRUITING

Norfolk, Virginia, 23507, United States
Investigational Site 002
RECRUITING

Santa Monica, California, 90404, United States
Investigational Site 003
RECRUITING

New York, New York, 10032, United States
Investigational Site 004
RECRUITING

Charlottesville, Virginia, 22903, United States
Investigational Site 005
RECRUITING

Austin, Texas, 78705, United States
Investigational Site 006
RECRUITING

Houston, Texas, 77030, United States
Investigational Site 007
RECRUITING

London, SE1 7EH, United Kingdom
Investigational Site 008
RECRUITING

Richmond, Virginia, 23284, United States
Investigational Site 009
RECRUITING

Cincinnati, Ohio, 45219, United States
Investigational Site 010
RECRUITING

Ottawa, Ontario, K1N 6N5, Canada
Investigational Site 011
RECRUITING

New York, New York, 10016, United States
Investigational Site 012
RECRUITING

London, EC1A 7BE, United Kingdom
Investigational Site 013
RECRUITING

Chicago, Illinois, 60611, United States
Investigational Site 014
RECRUITING

Los Angeles, California, 90048, United States
Investigational Site 015
RECRUITING

Barcelona, 08035, Spain
Investigational Site 016
RECRUITING

Madrid, 28850, Spain
Investigational Site 017
RECRUITING

Madrid, 28034, Spain
Investigational Site 018
RECRUITING

Valencia, 46015, Spain
Investigational Site 019
RECRUITING

Barcelona, 08017, Spain
Investigational Site 020
RECRUITING

Warsaw, 02-507, Poland
Investigational Site 021
RECRUITING

Milan, 20157, Italy
Investigational Site 022
RECRUITING

London, NW3 2QG, United Kingdom
Investigational Site 023
RECRUITING

Nea Ionia, 142 33, Greece
Investigational Site 024
RECRUITING

Voula, 166 73, Greece
Investigational Site 025
RECRUITING

Baltimore, Maryland, 21287, United States
Investigational Site 026
RECRUITING

Poitiers, 86000, France
Investigational Site 027
RECRUITING

Paris, 75013, France
Investigational Site 028
RECRUITING

Rochester, Minnesota, 55905, United States
Investigational Site 029
RECRUITING

Belgrade, 11040, Serbia
Investigational Site 030
RECRUITING

Belgrade, 1100, Serbia
Investigational Site 031
RECRUITING

Phoenix, Arizona, 85054, United States
Investigational Site 032
RECRUITING

Toulouse, 31400, France

Conditions

The condition(s) this trial relates to.

heart disorder idiopathic recurrent pericarditis pericarditis Recurrence

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HEART DISEASES HEART DISEASES PERICARDITIS PERICARDITIS RECURRENT PERICARDITIS